← Oncology Approval Tracker

FDA DECISION ·

Breyanzi

lisocabtagene maraleucel · Juno Therapeutics

FDA approvalNew therapyLarge B-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with large B-cell lymphoma that relapsed or was refractory following at least two systemic treatment lines, including DLBCL, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and grade 3B follicular lymphoma.

LAMPGEN ANALYSIS

Why it matters

The original CD19-directed CAR T approval covers a defined heavily treated large B-cell population.

What research teams should watch

Build referral, collection, manufacturing and infusion milestones into screening and follow-up.

PRIMARY RECORDS

Sources